-
May 15, 2023
The second scientific conference “Fundamentals of Cardiovascular Pharmacotherapy – Combination Therapy” was held in Sofia between May 12-14, 2023 on the initiative of the Academy-Cardiology Foundation, Logartis Foundation and Arbilis Ltd, in collaboration with the Bulgarian Society of Pharmacy and the National Association of General Practitioners in Bulgaria. As a leading manufacturer of combination products […]
-
January 10, 2023
Biser Georgiev: Supply disruptions and rising raw material prices could hamper antibiotic production
“We have assured quantities of medicines manufactured at Tchaikapharma High Quality Medicines. Based on current consumption, we maintain a minimum of a 4-month supply. If there is increased demand, we are ready to respond.”
-
December 6, 2022
Tchaikapharma’s latest medicinal product to receive marketing authorisation from the Bulgarian Drug Agency is Clopasa (colchicine) 0.5 mg tablets – the first gout treatment in the company’s broad portfolio. Clopasa belongs to the group of medicines with antipathic action. It is used for the treatment of acute attacks of gout, in the condition of […]
-
October 21, 2022
The newest medicinal product to receive Marketing Authorization from the Medicines Executive Agency is: Semefro 50 mg/850 mg film-coated tablets Semefro 50 mg/1000 mg film-coated tablets Active ingredients: sitagliptin/metformin hydrochloride Semefro contains two different medicines called sitagliptin and metformin. – Sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) […]
-
October 19, 2022
The turnover from transactions with Bulgarian shares reached just under BGN 6 million, and two-thirds of it (just over BGN 4 million) was formed by transactions with shares of Tchaikapharma High Quality Medicines. Another 4 companies formed another quarter of the turnover, SOFIX recorded a minimal decrease. Read the full article here in Bulgarian.